论文部分内容阅读
目的:观察喘可治注射液联合布地奈德福莫特罗治疗慢性阻塞性肺疾病(COPD)的疗效。方法:120例COPD患者随机分为2组,观察组予布地奈德福莫特罗吸入同时肌注喘可治注射液,对照组单纯给予布地奈德福莫特罗吸入。治疗28 d,比较两组FEV1%预计值、FEV1/FVC、6 min步行距离(6MWD)等肺功能指标变化和急性加重次数,同时观察治疗期间两组药物不良反应的发生情况。结果:治疗后2组肺功能和6 MWD均较前改善;观察组比对照组FEV1%预计值改善更明显[(59.7±12.1)%和(49.8±11.3)%,P<0.05],至少有1次急性加重的患者数明显减少(35%和62%,P<0.01),并且两组的药品不良反应发生率差异无统计学意义。结论:喘可治注射液联合布地奈德福莫特罗比单用布地奈德福莫特罗能更好地改善COPD患者的肺功能,减少急性加重次数,不会增加药品的不良反应发生率。
Objective: To observe the curative effect of Chuankezhi injection combined with budesonide formoterol on chronic obstructive pulmonary disease (COPD). Methods: One hundred and twenty patients with COPD were randomly divided into two groups. In the observation group, inhalation of budesonide formoterol and intramuscular injection of chuanxiong could be treated in the observation group. The control group was given inhaled budesonide formoterol alone. After 28 days of treatment, the changes of FEV1 / FVC, 6MWD (6MWD) and other pulmonary function indexes and the number of acute exacerbations were compared between the two groups. At the same time, the occurrence of adverse drug reactions in both groups were observed. Results: The lung function and 6 MWD of the two groups were improved after treatment. The predictive value of FEV1% in the observation group improved more significantly than that of the control group [(59.7 ± 12.1)% vs (49.8 ± 11.3)%, P <0.05] The number of patients with acute exacerbations was significantly reduced (35% vs 62%, P <0.01), and there was no significant difference in adverse drug reaction between the two groups. Conclusion: Chuankezhi injection combined with budesonide formoterol than budesonide formoterol can better improve lung function in COPD patients, reduce the number of acute exacerbations, and will not increase the incidence of adverse drug reactions .